Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata

Angela L Rachubinski; Belinda Enriquez Estrada; David Norris; Cory A Dunnick; Jennifer C Boldrick; Joaquin M Espinosa

doi:10.1016/j.jdcr.2019.02.007

Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata

JAAD Case Rep. 2019 Apr 5;5(4):365-367. doi: 10.1016/j.jdcr.2019.02.007. eCollection 2019 Apr.

Authors

Angela L Rachubinski^{1

2}, Belinda Enriquez Estrada¹, David Norris^{3

4}, Cory A Dunnick^{3

4}, Jennifer C Boldrick⁵, Joaquin M Espinosa^{1

6

7}

Affiliations

¹ Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
² Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
³ Department of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
⁴ Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado.
⁵ Palo Alto Medical Foundation, Palo Alto, California.
⁶ Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
⁷ Department of Molecular, Cellular and Developmental Biology, University of Colorado Boulder, Boulder, Colorado.

No abstract available

Keywords: AA, alopecia areata; DS, Down syndrome; Down syndrome; IFN, interferon; JAK, Janus kinase; Janus kinase inhibition; STAT, signal transducer activator of transcription; T21, trisomy 21; Xeljanz; alopecia areata; atopic dermatitis; autoimmunity; eczema; interferon; tofacitnib; trisomy 21; vitiligo.

Publication types

Case Reports